These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27684806)

  • 21. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
    Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T
    Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies.
    Qi WX; Fu S; Zhang Q; Guo XM
    Asian Pac J Cancer Prev; 2014; 15(19):8177-82. PubMed ID: 25339002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
    Qi P; Chen M; Zhang LX; Song RX; He ZH; Wang ZP
    PLoS One; 2015; 10(7):e0133803. PubMed ID: 26192308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
    Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
    J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
    Narita S; Tsuchiya N; Yuasa T; Maita S; Obara T; Numakura K; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
    Int J Clin Oncol; 2012 Jun; 17(3):204-11. PubMed ID: 21706123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.